MX2015015601A - Metodo para el tratamiento de cancer pulmonar por vacunacion con el lipopeptido mucina 1 (muc-1). - Google Patents
Metodo para el tratamiento de cancer pulmonar por vacunacion con el lipopeptido mucina 1 (muc-1).Info
- Publication number
- MX2015015601A MX2015015601A MX2015015601A MX2015015601A MX2015015601A MX 2015015601 A MX2015015601 A MX 2015015601A MX 2015015601 A MX2015015601 A MX 2015015601A MX 2015015601 A MX2015015601 A MX 2015015601A MX 2015015601 A MX2015015601 A MX 2015015601A
- Authority
- MX
- Mexico
- Prior art keywords
- lung cancer
- muc
- vaccination
- lipopeptide
- treating lung
- Prior art date
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title abstract 2
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 title abstract 2
- 201000005202 lung cancer Diseases 0.000 title abstract 2
- 208000020816 lung neoplasm Diseases 0.000 title abstract 2
- 238000002255 vaccination Methods 0.000 title abstract 2
- 108010028921 Lipopeptides Proteins 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 2
- 238000011127 radiochemotherapy Methods 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 2
- 238000002648 combination therapy Methods 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1735—Mucins, e.g. human intestinal mucin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0012—Lipids; Lipoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se relaciona con el tratamiento de cáncer pulmonar, de preferencia cáncer pulmonar de células no pequeñas (NSCLC), por medio de una terapia de combinación que comprende quimio-radioterapia concurrente seguido de la vacunación con un lipopéptido de muc-1. La terapia provoca tasas de supervivencia prolongadas comparadas con una terapia respectiva que incluye la quimio-terapia secuencial.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13002525 | 2013-05-14 | ||
PCT/EP2014/000992 WO2014183823A1 (en) | 2013-05-14 | 2014-04-14 | Method of treating lung cancer by vaccination with muc-1 lipopeptide |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015015601A true MX2015015601A (es) | 2016-03-03 |
Family
ID=48482889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015015601A MX2015015601A (es) | 2013-05-14 | 2014-04-14 | Metodo para el tratamiento de cancer pulmonar por vacunacion con el lipopeptido mucina 1 (muc-1). |
Country Status (11)
Country | Link |
---|---|
US (1) | US20160067322A1 (es) |
EP (1) | EP2996708A1 (es) |
JP (1) | JP2016520073A (es) |
KR (1) | KR20160007640A (es) |
CN (1) | CN105283199A (es) |
AU (1) | AU2014267749A1 (es) |
BR (1) | BR112015028252A2 (es) |
CA (1) | CA2912269A1 (es) |
MX (1) | MX2015015601A (es) |
SG (1) | SG11201509357WA (es) |
WO (1) | WO2014183823A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10441810B2 (en) * | 2007-04-08 | 2019-10-15 | Immunolight, Llc | X-ray psoralen activated cancer therapy (X-PACT) |
EP3365017A4 (en) | 2015-10-19 | 2019-04-17 | Immunolight, LLC | X-PACT ACTIVATED ANTI-CANCER TREATMENT BASED ON X-RAY-ACTIVATED PSORALENE |
KR102098097B1 (ko) | 2017-08-16 | 2020-05-26 | 주식회사 차백신연구소 | 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도 |
WO2019035605A2 (ko) * | 2017-08-16 | 2019-02-21 | 주식회사 차백신연구소 | 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69842060D1 (de) | 1997-05-08 | 2011-01-27 | Oncothyreon Inc | Verfahren zur Gewinnung aktivierter T-Zellen und mit Antigen-inkubierten Antigen-präsentierender Zellen |
TWI395591B (zh) | 2004-04-01 | 2013-05-11 | Oncothyreon Inc | 黏液性糖蛋白(muc-1)疫苗 |
BRPI0613510A2 (pt) * | 2005-06-28 | 2011-01-11 | Biomira Inc | processo de tratamento de pacientes com uma vacina de glicoproteìna mucinosa (muc-1) |
-
2014
- 2014-04-14 KR KR1020157035279A patent/KR20160007640A/ko not_active Application Discontinuation
- 2014-04-14 SG SG11201509357WA patent/SG11201509357WA/en unknown
- 2014-04-14 CA CA2912269A patent/CA2912269A1/en not_active Abandoned
- 2014-04-14 US US14/891,557 patent/US20160067322A1/en not_active Abandoned
- 2014-04-14 EP EP14719620.8A patent/EP2996708A1/en not_active Withdrawn
- 2014-04-14 BR BR112015028252A patent/BR112015028252A2/pt not_active IP Right Cessation
- 2014-04-14 MX MX2015015601A patent/MX2015015601A/es unknown
- 2014-04-14 WO PCT/EP2014/000992 patent/WO2014183823A1/en active Application Filing
- 2014-04-14 CN CN201480027425.XA patent/CN105283199A/zh active Pending
- 2014-04-14 AU AU2014267749A patent/AU2014267749A1/en not_active Abandoned
- 2014-04-14 JP JP2016513240A patent/JP2016520073A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20160007640A (ko) | 2016-01-20 |
CN105283199A (zh) | 2016-01-27 |
EP2996708A1 (en) | 2016-03-23 |
WO2014183823A1 (en) | 2014-11-20 |
US20160067322A1 (en) | 2016-03-10 |
AU2014267749A1 (en) | 2015-12-24 |
BR112015028252A2 (pt) | 2017-07-25 |
JP2016520073A (ja) | 2016-07-11 |
CA2912269A1 (en) | 2014-11-20 |
SG11201509357WA (en) | 2015-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501500A1 (en) | Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy | |
PH12017502154A1 (en) | Methods for conditioning patients for t cell therapy | |
MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
CL2015000699A1 (es) | Métodos para tratamiento de cáncer. | |
MX2016013600A (es) | Método para tratar adenocarcinoma de pulmón. | |
MX2018001755A (es) | Vacuna contra viruela para tratamiento del cancer. | |
MX2015014046A (es) | Combinaciones de farmacos para tratar cancer. | |
MX2015014599A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer. | |
SG10201804034QA (en) | Methods for treating hypotension | |
MX2015014344A (es) | Terapia contra el cancer. | |
WO2014172532A3 (en) | Methods for cancer treatment | |
EA201691385A1 (ru) | Комбинированная терапия рака | |
EP4353320A3 (en) | Blood plasma and plasma fractions as therapy for tumor growth and progression | |
MX2016016388A (es) | Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña. | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
MX2015015601A (es) | Metodo para el tratamiento de cancer pulmonar por vacunacion con el lipopeptido mucina 1 (muc-1). | |
CL2018001434A1 (es) | Terapia cíclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona | |
JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
WO2014145498A3 (en) | Therapeutic cancer vaccine targeted to haah (aspartyl-[asparaginyl]-beta-hydroxylase) | |
MX2018011379A (es) | Tratamiento del prurito uremico. | |
MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
PH12015502516A1 (en) | Efficacious treatment of nsclc and predictive clinical marker of the responsiveness of a tumour to a treatment | |
WO2014145142A3 (en) | Method of improving survival in cancer | |
PH12014502464A1 (en) | Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases | |
NZ631364A (en) | Filanesib combined with pomalidomide displays enhanced anti-tumor activity |